Christina Orsmark Pietras

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. Myeloid Cells 44%
3. Leukemia 39%
4. Precursor Cell Lymphoblastic Leukemia-Lymphoma 32%
5. Tumor Necrosis Factor Ligand Superfamily Member 13 29%
6. Whole Exome Sequencing 26%
7. RNA Sequence Analysis 23%
8. Toll-Like Receptor 1 22%
9. Asthma 22%
10. Transcriptome 21%
11. Gene Fusion 21%
12. Rhabdoid Tumor 21%
13. nucleophosmin 21%
14. Complement Receptors 19%
15. Apoptosis 18%
16. B-Lymphoid Precursor Cells 17%
17. Whole Genome Sequencing 16%
18. Platelet-Derived Growth Factor 16%
19. Validation Studies 15%
20. Precision Medicine 15%
21. p38 Mitogen-Activated Protein Kinases 14%
22. Gene Expression Profiling 14%
23. DNA Methylation 14%
24. Routine Diagnostic Tests 13%
25. Neoplasms 13%
26. Interleukin-4 13%
27. Mutation 13%
28. Pediatrics 12%
29. Single Nucleotide Polymorphism 12%
30. Cancer-Associated Fibroblasts 11%
31. Clone Cells 10%
32. Hematopoietic Stem Cells 10%
33. Messenger RNA 9%
34. Standard of Care 9%
35. Breast Neoplasms 9%
36. Therapeutics 8%
37. Cytokines 7%
38. Gene Expression 7%
39. Health Impact Assessment 7%
40. Methylation 7%
41. Economics 7%
42. Transcription Initiation Site 6%
43. Population 6%
44. Child 6%
45. Survival 5%
46. Stem Cells 5%
47. Genes 5%
48. Blast Crisis 5%
49. Nuclear Receptor Subfamily 1, Group F, Member 1 5%
50. Ecosystem 5%